Phase I/II Trial of Antagonism of HER in GI Cancer (PANTHER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01862003

Recruitment Status : Completed

First Posted : May 24, 2013

Last Update Posted : August 19, 2019

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Cancer Research UK

AstraZeneca

National Institute for Health Research, United Kingdom

Information provided by (Responsible Party):

University College, London

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	August 2, 2019
Actual Study Completion Date :	August 2, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Propper DJ, Gao F, Saunders MP, Sarker D, Hartley JA, Spanswick VJ, Lowe HL, Hackett LD, Ng TT, Barber PR, Weitsman GE, Pearce S, White L, Lopes A, Forsyth S, Hochhauser D. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. Br J Cancer. 2023 Jan;128(2):245-254. doi: 10.1038/s41416-022-02015-x. Epub 2022 Nov 9.

To Top